問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
翁昭旼
下載
2018-04-01 - 2019-12-31
Condition/Disease
Moderately to Severely Active Crohn's Disease
Test Drug
Upadacitinib (ABT-494)
Participate Sites4Sites
Recruiting3Sites
未分科
2018-04-01 - 2028-12-31
Participate Sites5Sites
Recruiting4Sites
2020-03-31 - 2028-01-27
2017-12-21 - 2020-04-01
Participate Sites6Sites
Recruiting5Sites
2016-10-10 - 2022-08-31
Participate Sites8Sites
Terminated3Sites
2018-06-01 - 2027-06-30
2018-11-01 - 2021-03-30
Moderately to Severely Active Ulcerative Colitis
Recruiting2Sites
Terminated2Sites
Division of Colorectal Surgery
2017-09-01 - 2020-01-31
Ulcerative Colitis
TJ301
Participate Sites2Sites
Digestive System Department
2017-02-17 - 2020-12-17
Crohn’s Disease
Filgotinib
Participate Sites13Sites
Recruiting8Sites
Division of General Internal Medicine
Active Crohn’s Disease
Filgotinib, 100 mg and 200 mg per tablet
Participate Sites14Sites
Recruiting9Sites
全部
